IRIS
RIZZI, Rita
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 8.681
EU - Europa 2.600
AS - Asia 906
SA - Sud America 8
Continente sconosciuto - Info sul continente non disponibili 5
AF - Africa 4
OC - Oceania 2
Totale 12.206
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 8.674
CN - Cina 802
SE - Svezia 654
IT - Italia 634
UA - Ucraina 435
DE - Germania 301
FI - Finlandia 240
GB - Regno Unito 140
FR - Francia 92
IE - Irlanda 41
IN - India 33
BE - Belgio 22
HK - Hong Kong 19
IR - Iran 10
CZ - Repubblica Ceca 9
RU - Federazione Russa 9
SG - Singapore 9
TR - Turchia 8
KR - Corea 6
PL - Polonia 6
CA - Canada 5
EU - Europa 5
NL - Olanda 4
VN - Vietnam 4
BR - Brasile 3
ES - Italia 3
RO - Romania 3
TW - Taiwan 3
AU - Australia 2
CO - Colombia 2
ET - Etiopia 2
ID - Indonesia 2
JP - Giappone 2
MA - Marocco 2
MX - Messico 2
PH - Filippine 2
TH - Thailandia 2
AL - Albania 1
AZ - Azerbaigian 1
BG - Bulgaria 1
BO - Bolivia 1
BY - Bielorussia 1
CL - Cile 1
DK - Danimarca 1
HR - Croazia 1
IL - Israele 1
KZ - Kazakistan 1
MD - Moldavia 1
MK - Macedonia 1
PE - Perù 1
UZ - Uzbekistan 1
Totale 12.206
Salva come PNG Salva come JPEG
Città #
Jacksonville 1.016
Chandler 1.011
Woodbridge 893
Fairfield 825
Houston 512
Nyköping 470
Ann Arbor 454
Ashburn 444
Cambridge 431
Seattle 321
Wilmington 294
Roxbury 256
Lawrence 241
Nanjing 238
Des Moines 161
Beijing 140
Bari 126
Boardman 125
New York 124
Inglewood 107
Princeton 89
Shenyang 71
Hebei 66
San Diego 55
Rome 52
Dearborn 51
Jiaxing 50
Brooklyn 48
Nanchang 45
Dublin 40
Changsha 39
Tianjin 37
Los Angeles 34
Paris 34
London 32
Pune 25
Florence 23
Redwood City 22
Brussels 21
Jinan 17
Milan 16
Noicattaro 16
Washington 16
Kunming 14
Guangzhou 13
Norwalk 13
West Jordan 13
Hefei 12
Ningbo 12
Augusta 11
Helsinki 11
Auburn Hills 10
Leawood 10
Ardabil 9
Orta Nova 9
San Mateo 8
Boydton 7
Chiswick 7
Melito Di Napoli 7
Zhengzhou 7
Kilburn 6
Marseille 6
Omice 6
Singapore 6
Indiana 5
Monmouth Junction 5
Radomsko 5
Torino 5
Trani 5
Alcamo 4
Bengaluru 4
Dong Ket 4
Fuzhou 4
Grafing 4
Imbersago 4
Modugno 4
Napoli 4
Noto 4
Taizhou 4
Tappahannock 4
Triggiano 4
Turin 4
Balıkesir 3
Baotou 3
Bitonto 3
Cerignola 3
Giovinazzo 3
Istanbul 3
Naples 3
Prescot 3
Randazzo 3
Seoul 3
Verona 3
Yellow Springs 3
Addis Ababa 2
Altamura 2
Assago 2
Azzano Decimo 2
Bisceglie 2
Bollate 2
Totale 9.410
Salva come PNG Salva come JPEG
Nome #
Leucemia linfatica cronica in trasformazione prolinfocitoide: descrizione di un caso 157
LIGHT/TNFSF14 as a new biomarker of bone disease in multiple myeloma patients experiencing therapeutic regimens 105
Continuous therapy in standard- and high-risk newly-diagnosed multiple myeloma: A pooled analysis of 2 phase III trials 103
Ofatumumab retreatment and maintenance in fludarabine-refractory chronic lymphocytic leukaemia patients 102
TRAIL effect on osteoclast formation in physiological and pathological conditions 102
Light/TNFSF14 increases osteoclastogenesis and decreases osteoblastogenesis in multiple myeloma-bone disease. 97
Vascular Endothelial Growth Factor Serum Levels Are Elevated in Patients with Hereditary Hemorrhagic Telangiectasia 96
"Real world" outcome of lenalidomide plus dexamethasone in the setting of recurrent and refractory multiple myeloma: Extended follow-up of a retrospective multicenter study by the "rete ematologica pugliese" 94
Behçet's disease: an immune-mediated vasculitis involving vessels of all sizes 93
Amyloid in bone marrow smears of patients affected by multiple myeloma 93
Non-treatment-related chronic myeloid leukemia as a second malignancy 92
Sclerostin is overexpressed by plasma cells from multiple myeloma patients 90
Rhabdomyolysis and acute tubular necrosis in coniine (hemlock)poisoning 90
Concomitant primary polycythemia vera and follicle center cell non-Hodgkin lymphoma: a case report and review of the literature 89
In vitro osteoclastogenesis and T-cell RANKL expression in multiple myeloma-bone disease at diagnosis and in the setting of frontline treatment 87
Autoimmune hemolytic anemia during interferon-alfa therapy for chronic hepatitis C 87
A case of AL amyloidosis associated with IgD multiple myeloma (MM): clinical and laboratory findings, and outcome 86
Takayasu’s arteritis: a cell mediated large vessel vasculitis 86
Autoimmune Myelofibrosis: report of three cases and review of the literature 85
Carfilzomib-Lenalidomide-Dexamethasone (KRd) Induction-Autologous Transplant (ASCT)-Krd Consolidation Vs KRd 12 Cycles Vs Carfilzomib-Cyclophosphamide-Dexamethasone (KCd) Induction-ASCT-KCd Consolidation: Analysis of the Randomized Forte Trial in Newly Diagnosed Multiple Myeloma (NDMM) 82
Hepatitis C virus infection and mixed cryoglobulinemia: a striking association 81
Early mortality in myeloma patients treated with first-generation novel agents thalidomide, lenalidomide, bortezomib at diagnosis: A pooled analysis 80
Malignant lymphoma involving a Warthin’s tumor: a case with immunophenotypic and gene rearrangement analysis 77
Cost of illness in patients with multiple myeloma in Italy: the CoMiM study 77
CD34CD2 Acute promyelocytic leukemia (APL): is this a distinct subset? 77
Maintenance in myeloma patients achieving complete response after upfront therapy: a pooled analysis 76
The role of OPG/TRAIL complex in multiple myeloma: the OPG/TRAIL complex in an in vitro osteoclastogenesis model derived from human multiple myeloma-bone disease 73
Infectious complications in patients with multiple myeloma treated with new drug combinations containing thalidomide 72
Infection complications in patients with multiple myeloma treated with new drug combinations including thalidomide 72
Schnitzler syndrome: validation and applicability of diagnostic criteria in real-life patients 72
Dexamethasone plus rituximab yields higher sustained response rates than dexamethasone monotherapy in adults with primary immune thrombocytopenia 71
A prospective randomized study comparing rituximab and dexamethasone vs dexamethasone alone in ITP: results of final analysis and long term follow up 71
Schnitzler's syndrome: diagnosis, treatment, and follow-up. 71
Thalidomide, dexamethasone, Doxil and Velcade (ThaDD-V) followed by consolidation/maintenance therapy in patients with relapsed-refractory multiple myeloma 71
Fludarabine, cyclophosphamide and lenalidomide in patients with relapsed/refractory chronic lymphocytic leukemia. A multicenter phase I–II GIMEMA trial 70
Considerations in the treatment of multiple myeloma: a consensus statement from Italian experts 70
Ibridizzazione in situ non isotopica. Attualità e prospettive 69
The Role of LIGHT in Multiple Myeloma-Bone Disease 69
Anti-endothelial cell antibodies (AECA) in a patient wiyh Takayasu’s arteritis. In: Pathogenesis and immunotherapy of autoimmune diseases. Final program and abstract book 68
Elotuzumab plus pomalidomide and dexamethasone in relapsed/refractory multiple myeloma: a multicenter, retrospective real-world experience with 200 cases outside of controlled clinical trials 67
A role of light as potential biomarker for progression of smoldering to symptomatic multiple myeloma 67
T cells support osteoclastogenesis in an in vitro model derived from human multiple myeloma bone disease: the role of the OPG/TRAIL interaction 66
Alteration of the osteogenic properties of bone marrow stromal cells from multiple myeloma bone disease patients 65
The OPG/TRAIL complex in an in vitro osteoclastogenesis model derived from human multiple myeloma-bone disease 65
Myeloma cells suppress osteoblasts through sclerostin secretion 65
Soluble CD4 antigen reactivity in intravenous immunoglobulin preparations: is it specific? 65
null 65
Alteration of bone remodeling in multiple myeloma bone disease: role of sclerostin 64
Clinical spectrum of accidental hemlock poisoning: neurotoxic manifestations, rhabdomyolysis and acute tubular necrosis 63
A phase II study of chlorambucil plus rituximab followed by maintenance versus observation in elderly patients with previously untreated chronic lymphocytic leukemia: Results of the induction phase 63
A weekly infusion of bortezomib reduces peripheral neuropathy 63
Exploratory survey on multiple myeloma patients' perception 62
Livelli sierici di VEGF in pazienti affetti da Sindrome di Rendu-Osler-Weber 62
The role of multiparameter flow cytometry in the work-up of IGM-monoclonal gammopathies 62
Amyloidosis: clinical picture, immunological and biomolecular features, treatment prospects 61
Aneurysms of the supra-aortic trunks in Takayasu's disease - Report of two cases 61
Physician-Patient relationship: intervention opportunities for multiple myeloma patients'needs 61
Spontaneous remission of "methotrexate-associated lymphoproliferative disorders" after discontinuation of immunosuppressive treatment for autoimmune disease. Review of the literature 61
A phase II Study of chlorambucil plus rituximab followed by maintenance versus observation in elderly patients with previously untreated chronic lymphocytic leukemia: results of the first interim analysis 61
Real world Italian experience of pomalidomide plus low-dose dexamethasone in the relapsed and refractory myeloma setting: extended follow-up of a retrospective multicenter study by the ‘Rete Ematologica Pugliese E Basilicata’ 61
T cells support the osteoclastogenesis in an in vitro model derived from human multiple myeloma bone disease 60
Bendamustine, Bortezomib and Dexamethasone (BVD) in patients with relapsed-refractory multiple myeloma (MM): updated results of a multicenter phase II study. 60
Chlorambucil plus rituximab with or without maintenance rituximab as first-line treatment for elderly chronic lymphocytic leukemia patients. 60
T cells support the in vitro formation of osteoclasts in multiple myeloma-bone disease: the role of OPG/TRAIL interaction 59
FLAG-IDA in the treatment of refractory/relapsed adult acute lymphoblastic leukemia 59
A case of light chain (AL) amyloidosis associated with IgD Multiple Myeloma (MM): clinical features, laboratory findings and outcome 59
T cells support osteoclastogenesis in an in vitro model derived from psoritic arthritis 58
Acute tubular necrosis in the hemlock poisoning 58
Anti-endothelial cell antibodies in Wegener’s granulomatosis and micropolyarteritis 57
Diagnostic framing of IgM monoclonal gammopathy: Focus on Waldenstrom Macroglobulinemia 57
Analysis of percent identity of IGHV mutation as prognostic factor in CLL patients treated with fludarabine, cyclofosfamide and rituximab: a single centre experience 57
Rituximab plus chlorambucil as initial treatment for elderly patients with chronic lymphocytic leukemia (CLL): effect of pre-treatment biological characteristics and gene expression patterns on response to treatment 56
P-ANCA atipici nelle malattie infiammatorie croniche intestinali 56
Altered osteogenic properties of bone marrow stromal cells from multiple myeloma patients 56
Enoxaparin, aspirin, or warfarin for thromboprophilaxis in newly diagnosed myeloma patients receiving thalidomide: a randomized controlled trial 55
Microvessel density and angiogenic cytokine expression in autoimmune myelofibrosis compared with chronic idiopathic myelofibrosis 55
Thalidomide, dexamethasone, doxil and velcade (ThaDD-V) induction therapy followed by consolidation-maintenance is very effective in early relapsed/refractory MM 55
Another link between bone and immune system: LIGHT 55
L'AMILOIDOSI: QUADRI CLINICI, CARATTERISTICHE IMMUNOLOGICHE E BIOMOLECOLARI, PROSPETTIVE TERAPEUTICHE 55
Angiogenesis and hereditary hemorrhagic telangiectasia. Rendu-Osler-Weber disease 55
Rhabdomyolysis and acute tubular necrosis in hemlock poisoning 54
Economic and social burden of multiple myeloma in Italy – Co.Mi.M. Study 54
The role of molecular genetics in the diagnosis of lymphoma 53
Alterazione delle capacità osteogeniche in cellule stromali ottenute da midollo osseo di pazienti affetti da mieloma multiplo 53
Soluble Decoy Receptor 3 (DcR3) modulates the survival and formation of osteoclasts from multiple myeloma bone disease patients 53
Antigene CD4 solubile nei preparati di immunoglobuline umane per vie endovenosa 53
Kidney damage by ingestion of ethylene glicol 52
Anticorpi monoclonali anti-idiotipo (Ab2) anti-CD4 inducono anticorpi anti-CD4 in un sistema singenico 52
FLAG-IDA in the treatment of refractory/relapsed acute myeloid leukemia: single-center experience 52
Anti-endothelial cell autoantibodies in patients with Behcet’s disease 52
Gemtuzumab ozogamicin with cytarabine and mitoxantrone as a third-line treatment in a poor prognosis group of adult acute myeloid leukemia patients: a single-center experience 52
Myeloma cells induce osteoblast suppression through sclerostin secretion 52
Anemia emolitica autoimmune sviluppata durante il trattamento di epatite cronica C con interferone-alfa 51
Bendamustina in associazione a Rituximab in una paziente con leucemia linfatica cronica "highest risk" pluritrattata 51
Autoimmune bone marrow fibrosis: a distinct clinicopathological entity 51
Bone marrow angiogenesis in autoimmune myelofibrosis 51
A Phase III study of enoxaparin versus aspirin versus low-dose warfarin as thrombophylaxis for patients with newly diagnosed multiple myeloma treated up-front with thalidomide based-regimens 51
Failure of an in vitro model of osteoclastogenesis in human plasma cell leukaemia (PCL) 51
Anti-endothelial cell autoantibodies in Takayasu’s arteritis 50
The economic and social burden of multiple myeloma in Italy. The CO.MI.M. study 50
Totale 6.813
Salva come PNG Salva come JPEG
Categoria #
all - tutte 49.946
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 49.946
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2018/2019437 0 0 0 0 0 0 0 0 0 0 189 248
2019/20202.672 579 177 49 166 261 151 325 174 314 131 302 43
2020/20211.949 197 63 167 68 306 101 234 126 204 242 151 90
2021/20221.790 78 253 7 128 56 77 73 96 126 79 314 503
2022/20232.648 380 231 111 271 344 375 41 300 495 16 45 39
2023/20241.087 200 212 73 66 97 238 66 69 8 55 3 0
Totale 12.510